{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:39:52Z","timestamp":1792805992137,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118611","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:45:00Z","timestamp":1759538700000},"page":"118611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting metabolic syndrome with ALIAmides: A novel multi-mechanistic approach"],"prefix":"10.1016","volume":"192","author":[{"given":"Irene","family":"Palenca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Masulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rurgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2025.118611_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118611_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118611_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: pathophysiology, management, and modulation by natural compounds","volume":"11","author":"Rochlani","year":"2017","journal-title":"Ther. Adv. Cardiovasc Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118611_bib5","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12902-024-01738-7","article-title":"The effect of oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial","volume":"24","author":"Ostadrahimi","year":"2024","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1096\/fj.201901510RR","article-title":"Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice","volume":"34","author":"Annunziata","year":"2020","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/mol.104.006353","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide","volume":"67","author":"Lo Verme","year":"2005","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gutjnl-2013-305005","article-title":"Palmitoylethanolamide improves colon inflammation through an enteric glia\/toll like receptor 4-dependent PPAR-\u03b1 activation","volume":"63","author":"Esposito","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2025.118611_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbi.2025.02.014","article-title":"Oleoylethanolamide-producing lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese Male mice","volume":"127","author":"Seguella","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.biopha.2025.118611_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tibs.2010.05.008","article-title":"Intracellular trafficking of anandamide: new concepts for signaling","volume":"35","author":"Maccarrone","year":"2010","journal-title":"Trends Biochem Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.pain.2008.06.003","article-title":"The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors","volume":"139","author":"Costa","year":"2008","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.biopha.2025.118611_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MOL.0b013e32803dbdec","article-title":"Endocannabinoids and the regulation of their levels in health and disease","volume":"18","author":"Di Marzo","year":"2007","journal-title":"Curr. Opin. Lipido"},{"key":"10.1016\/j.biopha.2025.118611_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","article-title":"Endocannabinoids and their pharmacological actions","volume":"231","author":"Pertwee","year":"2015","journal-title":"Handb. Exp. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jcmgh.2020.10.001","article-title":"Impaired duodenal palmitoylethanolamide release underlies Acid-Induced mast cell activation in functional dyspepsia","volume":"11","author":"Sarnelli","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118611_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118611_bib17","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"issue":"19","key":"10.1016\/j.biopha.2025.118611_bib18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2025.118611_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"issue":"7203","key":"10.1016\/j.biopha.2025.118611_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07202","article-title":"Integration of metabolism and inflammation by lipid-activated nuclear receptors","volume":"454","author":"Bensinger","year":"2008","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.biopha.2025.118611_bib22","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.3390\/nu16244313","article-title":"Palmitoylethanolamide in postmenopausal metabolic syndrome: current evidence and clinical perspectives","volume":"16","author":"Medoro","year":"2024","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.biopha.2025.118611_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/pharmaceutics14020338","article-title":"Palmitoylethanolamide promotes White-to-Beige conversion and metabolic reprogramming of adipocytes: contribution of PPAR-\u03b1","volume":"14","author":"Annunziata","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118611_bib24","doi-asserted-by":"crossref","DOI":"10.32604\/biocell.2025.061606","article-title":"Mechanistic insights into N-Oleoylethanolamide-Mediated hepatoprotection via PPAR-\u03b1","author":"Ivashkevich","year":"2025","journal-title":"Biocell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085337","article-title":"Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/futurepharmacol3040058","article-title":"Therapeutic use of palmitoylethanolamide as an Anti-Inflammatory and immunomodulator","volume":"3","author":"S\u00e1","year":"2023","journal-title":"Future Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib28","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/nu11081956","article-title":"Lifestyle and metabolic syndrome: contribution of the endocannabinoidome","volume":"11","author":"Di Marzo","year":"2019","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.biopha.2025.118611_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1101\/lm.1145209","article-title":"Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors","volume":"16","author":"Mazzola","year":"2009","journal-title":"Learn Mem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a g protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.biopha.2025.118611_bib31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118611_bib32","doi-asserted-by":"crossref","first-page":"C145","DOI":"10.1007\/BF01972748","article-title":"A proposed autacoid mechanism controlling mastocyte behaviour","volume":"39","author":"Aloe","year":"1993","journal-title":"Agents Actions"},{"issue":"11","key":"10.1016\/j.biopha.2025.118611_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.13580","article-title":"The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations","volume":"174","author":"Petrosino","year":"2017","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118611_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1144550","article-title":"Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: a randomized controlled trial","volume":"14","author":"Tutunchi","year":"2023","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib35","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13517","article-title":"Oleoylethanolamide-induced anorexia in rats is associated with locomotor impairment","volume":"6","author":"Fedele","year":"2018","journal-title":"Physiol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib36","doi-asserted-by":"crossref","first-page":"R729","DOI":"10.1152\/ajpregu.00029.2005","article-title":"Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity","volume":"289","author":"Proulx","year":"2005","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2005.02.013","article-title":"Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats","volume":"48","author":"Fu","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118611_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104770","article-title":"Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: effects on metabolic parameters, anthropometric indices, and expression of PPAR-\u03b1, UCP1, and UCP2 genes","volume":"156","author":"Tutunchi","year":"2020","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1096\/fj.201901510RR","article-title":"Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice","volume":"34","author":"Annunziata","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118611_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744483","article-title":"Micronized palmitoylethanolamide ameliorates Methionine- and Choline-Deficient Diet-Induced nonalcoholic steatohepatitis via inhibiting inflammation and restoring autophagy","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118611_bib41","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.118.311185","article-title":"Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation","volume":"38","author":"Rinne","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/nu17030413","article-title":"The effects of a food supplement, based on Co-Micronized palmitoylethanolamide (PEA)\u2013Rutin and hydroxytyrosol, in metabolic syndrome patients: preliminary results","volume":"17","author":"Cornali","year":"2025","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10193","key":"10.1016\/j.biopha.2025.118611_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.biopha.2025.118611_bib45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"21","key":"10.1016\/j.biopha.2025.118611_bib46","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000195790.24531.4f","article-title":"Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome","volume":"26","author":"Szapary","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2025.118611_bib48","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.biopha.2025.118611_bib49","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/oby.24177","article-title":"Weight maintenance on cost-effective antiobesity medications after 1\u2009year of GLP-1 receptor agonist therapy: a real-world study","volume":"32","author":"Paddu","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2025.118611_bib50","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"issue":"11","key":"10.1016\/j.biopha.2025.118611_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of Sodium-Glucose Co-Transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and Meta-Analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118611_bib52","article-title":"Achieving equitable access to incretin-based therapies in cardiovascular care","volume":"46","author":"Reddy","year":"2024","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2025.118611_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.554961","article-title":"Multi-Target approaches in metabolic syndrome","volume":"11","author":"Lillich","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118611_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib55","doi-asserted-by":"crossref","first-page":"F449","DOI":"10.1152\/ajprenal.00431.2018","article-title":"Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells","volume":"316","author":"Pirklbauer","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118611_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Res. Clin. Pr."},{"key":"10.1016\/j.biopha.2025.118611_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1751-7176.2011.00490.x","article-title":"Overcoming obstacles in risk factor management in type 2 diabetes mellitus","volume":"13","author":"Handelsman","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.biopha.2025.118611_bib58","first-page":"137","article-title":"Selected polyphenolic compounds and their use as a supportive therapy in metabolic syndrome","volume":"71","author":"Soukop","year":"2022","journal-title":"Ceska. Slov. Farm"},{"issue":"24","key":"10.1016\/j.biopha.2025.118611_bib59","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1523\/JNEUROSCI.0036-10.2010","article-title":"The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin","volume":"30","author":"Gaetani","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118611_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.appet.2018.05.129","article-title":"Oleoylethanolamide increases the expression of PPAR-\u0391 and reduces appetite and body weight in obese people: a clinical trial","volume":"128","author":"Laleh","year":"2018","journal-title":"Appetite"},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib61","doi-asserted-by":"crossref","first-page":"R595","DOI":"10.1152\/ajpregu.00459.2017","article-title":"Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice","volume":"315","author":"Brown","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118611_bib62","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/obr.12853","article-title":"The effects of oleoylethanolamide, an endogenous PPAR-\u03b1 agonist, on risk factors for NAFLD: a systematic review","volume":"20","author":"Tutunchi","year":"2019","journal-title":"Obes. Rev."},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib63","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/antiox10081289","article-title":"Oleoylethanolamide reduces hepatic oxidative stress and endoplasmic reticulum stress in High-Fat Diet-Fed rats","volume":"10","author":"Giudetti","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2025.118611_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2019.05.032","article-title":"Investigation the effect of oleoylethanolamide supplementation on the abundance of akkermansia muciniphila bacterium and the dietary intakes in people with obesity: a randomized clinical trial","volume":"141","author":"Payahoo","year":"2019","journal-title":"Appetite"},{"issue":"10","key":"10.1016\/j.biopha.2025.118611_bib65","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.3390\/ijms22105305","article-title":"Palmitoylethanolamide: a natural compound for health management","volume":"22","author":"Clayton","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118611_bib66","first-page":"237","article-title":"Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma","volume":"13","author":"Esposito","year":"2013","journal-title":"Mini Rev. Med Chem."},{"key":"10.1016\/j.biopha.2025.118611_bib67","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fphar.2019.00821","article-title":"Palmitoylethanolamide (PEA) as a potential therapeutic agent in alzheimer's disease","volume":"10","author":"Beggiato","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118611_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1742-2094-9-49","article-title":"Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-\u03b1","volume":"9","author":"Scuderi","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib69","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/ph16040621","article-title":"Oleoylethanolamide protects against acute ischemic stroke by promoting PPAR\u03b1-Mediated Microglia\/Macrophage M2 polarization","volume":"16","author":"Li","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib70","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.neuropharm.2005.01.001","article-title":"Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies","volume":"48","author":"Darmani","year":"2005","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib71","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbi.2012.07.021","article-title":"Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice","volume":"26","author":"Ahmad","year":"2012","journal-title":"Brain Behav. Immun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118611_bib72","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/npp.2012.25","article-title":"Palmitoylethanolamide protects against the amyloid-\u03b225-35-induced learning and memory impairment in mice, an experimental model of alzheimer disease","volume":"37","author":"D'Agostino","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.biopha.2025.118611_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136654","article-title":"Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPAR\u03b1","volume":"5","author":"Patel","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.biopha.2025.118611_bib74","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/biomedicines12071620","article-title":"Effect of palmitoylethanolamide compared to a placebo on the gut microbiome and biochemistry in an overweight adult population: a randomised, placebo controlled, Double-Blind study","volume":"12","author":"Batacan","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bph.12907","article-title":"Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent","volume":"172","author":"Borrelli","year":"2015","journal-title":"Br. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib76","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/ijms22062945","article-title":"Engineered lactobacillus paracasei producing palmitoylethanolamide (PEA) prevents colitis in mice","volume":"22","author":"Esposito","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118611_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639728","article-title":"A palmitoylethanolamide producing lactobacillus paracasei improves clostridium difficile toxin A-Induced colitis","volume":"12","author":"Esposito","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118611_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1143004","article-title":"Palmitoylethanolamide counteracts high-fat diet-induced gut dysfunction by reprogramming microbiota composition and affecting tryptophan metabolism","volume":"10","author":"Pirozzi","year":"2023","journal-title":"Front. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118611_bib79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12974-019-1671-5","article-title":"Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity","volume":"16","author":"Petrosino","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"17","key":"10.1016\/j.biopha.2025.118611_bib80","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1111\/bph.12759","article-title":"Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB\u2081 receptors and TRPV1 channels","volume":"171","author":"Capasso","year":"2014","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a g protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib82","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The Microbiota-Gut-Brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118611_bib83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/antiox13050600","article-title":"Therapeutic potential of palmitoylethanolamide in gastrointestinal disorders","volume":"13","author":"Brankovi\u0107","year":"2024","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/antiox10030464","article-title":"PEA\/Polydatin: Anti-Inflammatory and antioxidant approach to counteract DNBS-Induced colitis","volume":"10","author":"Peritore","year":"2021","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib85","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867023370707","article-title":"The palmitoylethanolamide family: a new class of anti-inflammatory agents?","volume":"9","author":"Lambert","year":"2002","journal-title":"Curr. Med Chem."},{"issue":"8","key":"10.1016\/j.biopha.2025.118611_bib86","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biopha.2025.118611_bib87","doi-asserted-by":"crossref","first-page":"479","DOI":"10.15171\/apb.2018.056","article-title":"Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial","volume":"8","author":"Payahoo","year":"2018","journal-title":"Adv Pharm Bull"},{"issue":"6830","key":"10.1016\/j.biopha.2025.118611_bib88","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib89","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/nu15061350","article-title":"Palmitoylethanolamide in the treatment of chronic pain: a systematic review and Meta-Analysis of Double-Blind randomized controlled trials","volume":"15","author":"Lang-Illievich","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2025.118611_bib90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fphar.2018.00249","article-title":"Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal Anti-hyperalgesic effect","volume":"9","author":"Petrosino","year":"2018","journal-title":"Front. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib91","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00018-004-4494-0","article-title":"Regulation of food intake by oleoylethanolamide","volume":"62","author":"Lo Verme","year":"2005","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.biopha.2025.118611_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1143004","article-title":"Palmitoylethanolamide counteracts high-fat diet-induced gut dysfunction by reprogramming microbiota composition and affecting tryptophan metabolism","volume":"10","author":"Pirozzi","year":"2023","journal-title":"Front. Nutr."},{"issue":"6","key":"10.1016\/j.biopha.2025.118611_bib93","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/nu15061350","article-title":"Palmitoylethanolamide in the treatment of chronic pain: a systematic review and Meta-Analysis of Double-Blind randomized controlled trials","volume":"15","author":"Lang-Illievich","year":"2023","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.biopha.2025.118611_bib94","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/en.2013-1823","article-title":"Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats","volume":"155","author":"Mattace Raso","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2025.118611_bib95","doi-asserted-by":"crossref","first-page":"C145","DOI":"10.1007\/BF01972748","article-title":"A proposed autacoid mechanism controlling mastocyte behaviour","volume":"39","author":"Aloe","year":"1993","journal-title":"Agents Actions"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:30:50Z","timestamp":1775781050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":95,"alternative-id":["S0753332225008054"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118611","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting metabolic syndrome with ALIAmides: A novel multi-mechanistic approach","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118611"}}